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Background: For all medications, there is a trade-off between benefits and potential for harm. 
It is important for patient safety to detect drug-event combinations and analyze by appropri-
ate statistical methods. Mefloquine is used as chemoprophylaxis for travelers going to regions 
with known chloroquine-resistant Plasmodium falciparum malaria. As such, there is a concern 
about serious adverse events associated with mefloquine chemoprophylaxis. The objective of 
the present study was to assess whether any signal would be detected for the serious adverse 
events of mefloquine, based on data in clinicoepidemiological studies.
Materials and methods: We extracted data on adverse events related to mefloquine chemopro-
phylaxis from the two published datasets. Disproportionality reporting of adverse events such as 
neuropsychiatric events and other adverse events was presented in the 2 × 2 contingency table. 
Reporting odds ratio and corresponding 95% confidence interval [CI] data-mining algorithm 
was applied for the signal detection. The safety signals are considered significant when the ROR 
estimates and the lower limits of the corresponding 95% CI are $2.
Results: Two datasets addressing adverse events of mefloquine chemoprophylaxis (one from 
a published article and one from a Cochrane systematic review) were included for analyses. 
Reporting odds ratio 1.58, 95% CI: 1.49–1.68 based on published data in the selected article, 
and 1.195, 95% CI: 0.94–1.44 based on data in the selected Cochrane review. Overall, in both 
datasets, the reporting odds ratio values of lower 95% CI were less than 2.
Conclusion: Based on available data, findings suggested that signals for serious adverse events 
pertinent to neuropsychiatric event were not detected for mefloquine. Further studies are needed 
to substantiate this.
Keywords: mefloquine, signal detection, reporting odds ratio, neuropsychiatric events
Introduction
With increasing international travel across countries, including those in malaria-
endemic regions, and the continued spread of resistance to antimalarial drugs, travelers 
are at risk for contracting malaria.1 Travelers who are naturally vulnerable because of 
lowered immunity, such as young children, people with chronic diseases, elderly people, 
and pregnant women, now travel more frequently; consequently, imported malaria is 
observed more often in these subgroups.2,3 Although imported malaria is preventable, 
many travelers fail to use or comply with appropriate chemoprophylaxis due to concerns 
regarding side effects associated with antimalarial chemoprophylaxis.4
There is a consensus that the ideal chemoprophylactic medication should be highly 
effective, cause few or no adverse events (AEs), be appropriate for all travelers, includ-
ing pregnant women, nursing mothers, small children, long-term travelers, should 
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be cheap and easy to use and should be registered globally 
for this indication.5 An AE is classified as “any undesirable 
medical occurrence that develops after the administration of 
a drug, regardless of the suspected relationship between the 
drug product and the event”. In order to classify an event as 
an adverse drug reaction (ADR), a causal relationship must be 
established.6,7 In the present analysis, a serious adverse event 
(SAE) was defined as any adverse experience that resulted in 
death, a life-threatening experience, participant hospitaliza-
tion, or persistent or significant disability or incapacity. We 
also examined specific medical or surgical intervention to 
prevent serious outcomes.8,9
Currently, three main antimalarial drugs, atovaquone-
proguanil, doxycycline, and mefloquine (MFQ), are used as 
chemoprophylaxis for those traveling to regions with known 
chloroquine-resistant Plasmodium falciparum malaria.4
MFQ has been available for malaria chemoprophylaxis 
since 1985 in Europe and since 1990 in the USA.5 Due to 
the drug’s characteristics of schizontocidal action against 
the blood stages of all human malaria species including 
P. knowlesi,10 its affordability, and because it is administered 
once weekly resulting in good adherence, MFQ is an effective 
malaria chemoprophylaxis for travelers going to high risk 
chloroquine-resistant P. falciparum areas5 in the Thai border 
regions known to have multidrug resistance.5 To date, the 
drug is used clinically as a 50:50 racemic mixture of the 
erythro isomers and all clinical studies involving this drug 
have used this mixture.5
The Cochrane systematic review incorporated eight 
randomized controlled trials (RCTs) with 4240 participants 
to assess currently used antimalarial drugs including MFQ 
for chemoprophylaxis of malaria in travelers. In the review, 
no SAEs were reported.4 Overall, pregnant women who took 
MFQ at various doses for both prevention and treatment 
of malaria did not have an increased risk of teratogenic 
effects (birth defects) or adverse pregnancy outcomes com-
pared to the background rate in the general population.11 
In contrast, the risk of AEs, particularly neuropsychiatric 
AEs, related to the prophylactic use of MFQ, has also been 
reported,1 which adversely affects compliance12 or may result 
in switching to less-effective alternatives. Studies have also 
identified severe psychiatric side effects related to the use 
of MFQ in preventing malaria.13,14 A study involving US 
military personnel deployed to Afghanistan reported that 
approximately one in seven individuals with neuropsychiatric 
contraindications received a prescription for MFQ prior to 
combat deployment.15 Thus, from the aspect of patient safety, 
potential harm to the prospective users must be identified.
Pharmacovigilance is defined as “the science and activi-
ties relating to the detection, assessment, understanding and 
prevention of adverse effects or any other possible drug related 
problem”.6,9 Two broad approaches for pharmacovigilance are 
used in developed countries, including passive spontaneous 
reporting systems and systems utilizing pharmacoepidemio-
logical methods.7,16 The latter approach can be applied to data 
from clinical trials if the sample size is adequate to assess risks 
in multiple arm treatments and if the collection of safety data 
is standardized to ensure high quality.7
Materials and methods
Study objective
The aim of the present study was to identify signals of 
SAEs resulting from the use of MFQ based on data from 
clinicoepidemiological studies.
Data source
In order to illustrate the signal detection for identifying SAEs 
in travelers taking MFQ for chemoprophylaxis, data from two 
sources, an individual study and the pooled data of RCTs, 
were extracted. We collected AE-related data from published 
studies and from a Cochrane systematic review. The data 
were from the empirical studies rather than that submitted 
by physicians, pharmacists, other health care professionals, 
manufacturers, or consumers. However, these data could be 
regarded as being spontaneously reported AEs by researchers 
because they (i) highlight the disproportionality, (ii) allow 
for estimation of relative risks, (iii) can give rise to less bias 
than case reports, and (iv) are available for calculations of 
disproportionality based upon presentation in a 2 × 2 con-
tingency table. In order to reflect the spontaneous reporting 
manner, we collected data according to the year the study 
was conducted. If duplicate reports for the same patient but 
from different sources were noted, only the latest updated 
data were included.
Clinical judgment was applied to identify neuropsychiat-
ric events as defined by the medical dictionary for regulatory 
activities preferred terms (Table 1).17
Data analyses
The association between antimalarial drugs, including MFQ, 
and neuropsychiatric events was analyzed using the reporting 
odds ratio (ROR) and corresponding 95% confidence interval 
(CI) data-mining algorithm. ROR values for MFQ denote 
the ratio of the observed to the expected number of reported 
neuropsychiatric events compared with other antimalarial 
drugs in the data set during the analysis period. Values less 
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Results
Two data sets were identified for this analysis. The Barrett 
data19 compared MFQ and a combination drug of chloroquine 
and proguanil. The Cochrane database4 assessed multiple 
comparisons including MFQ, atovaquone-proguanil, and 
doxycycline. Regarding the source of data collection, the 
former was from a retrospective survey (n = 1214 adults), 
while the latter was from eight RCTs (n = 4240 adults). The 
distribution of SAEs in travelers taking MFQ as a chemo-
prophylaxis and the respective data sources19–22 are shown 
in Tables 3 and 4.
Based on our estimates from of the two database sources, 
the estimated RORs and their corresponding 95% CI data-
mining algorithm for MFQ are presented in Tables 5 and 6. 
In both data sources, ROR values with low 95% CI values 
were less than 2. This indicates that signals for SAE pertinent 
to neuropsychiatric events were not detected.
Discussion
For all medications, there is a trade-off between the benefits 
and the potential for harm; these factors should be analyzed 
and communicated effectively as part of an effective approach 
towards pharmacovigilance.6 Anecdotal reports can identify 
the occurrence of an AE that may be coincidental23 rather 
than actual harm. It is important for patient safety to detect 
drug-event combinations and analyze these events using 
appropriate statistical methods.24,25 The present study pro-
vides information regarding the safety level of MFQ in adult 
travelers in the context of pharmacovigilance. As the ROR 
estimates and the lower limits of the corresponding 95% CI 
were 2 in both database sources in the present analysis, a 
safety signal was not detected.
Upon comparison of MFQ with the single comparator qui-
nine or a combination drug (ie, chloroquine plus proguanil) 
in the present analysis, “signal dilution”26 was not observed. 
As data collection is expensive, data-mining processes are 
often performed using existing databases for the purpose of 
pharmacovigilance.6,27 Regarding the methodology of the 
than 1 indicate no exposure-event association, while values 
greater than 1 indicate exposure-event safety signals. From 
the regulatory science perspective, safety signals are consid-
ered significant when the ROR estimates and the lower limits 
of the corresponding 95% CI are $2.18
Table 2 shows the data-mining algorithm to calculate 
point estimates of ROR and the corresponding 95% CI for 
MFQ and comparators in the study. Data entry and analy-
ses were performed using a Microsoft Excel (Microsoft, 
Redmond, WA) spreadsheet.
Table 3 Distribution of adverse events in travelers taking 
mefloquine chemoprophylaxis
Adverse events Reported serious AE Remarks
MFQ  
alone
Chloroquine  
plus proguanil
Nervous system AE 31 12 Serious AE
gI-related AE 26 16 Nonserious AE
Other nonserious AE 20 19 Nonserious AE
Notes: Derived from data in Barretts et al.19
Abbreviations: AE, adverse event; GI, gastrointestinal symptoms; MFQ, mefloquine.
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Table 1 Selected MedDRA preferred terms that reflect 
neuropsychiatric events
Category Preferred terms
Delirium Delirium 
Delirium febrile
Delusions/perceptual  
disturbance
Delusion 
Delusional perception 
Hallucination 
Hallucination, auditory 
Hallucination, visual 
Hallucinations, mixed 
Illusion 
Paranoia
Suicidal events Completed suicide 
Self-injurious behavior 
Self-injurious ideation 
Suicidal ideation 
Suicide attempt
Convulsion grand mal convulsion 
Clonic convulsion 
Convulsion 
Epilepsy 
Febrile convulsion 
Partial seizures 
Status epilepticus 
Tonic convulsion
Depressed level  
of consciousness
Altered state of consciousness 
Consciousness fluctuating 
Depressed level of consciousness
Abnormal behavior Abnormal behavior
Note: Each term category has multiple verbatim terms identified.
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.
Table 2 The 2 × 2 contingency table used for calculating reporting 
odds ratios and 95% CI data-mining algorithm
Exposure Neuropsychiatric  
events
Other  
AEs
Total
Mefloquine A B A + B
Other antimalarial drugs C D C + D
Total A + C B + D N
ROR: A/B 
C/D 
95% CI: e ln(ROR) ± 1.96 √1/A + 1/B + 1/C
Abbreviations: AE, adverse event; ROR, reporting odds ratio.
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data-mining process, measures of disproportionality are the 
only techniques which have been used to identify AEs.27 The 
current analysis followed this approach as well.
Spontaneous reporting to the World Health Organization 
or to the Food and Drug Administration may provide data on a 
broad spectrum of patients. Moreover, ADRs that occur after 
prolonged exposure or ADRs that are extremely rare can be 
detected through spontaneous reports. However, the absence 
of a control group and the lack of a denominator indicate that 
the attributable rate of the ADR cannot be calculated.28 Case 
reports are the main source of information used to withdraw 
a drug from the market for safety reasons.29 In assessing the 
culprit drug, it is difficult to determine whether the report 
is a genuine alert or a false alarm.30 The aim of the pres-
ent study was not to examine the reporting system, but to 
highlight the usefulness of other published data sources for 
signal detection.
The risk of malaria during travel is determined by immu-
nological characteristics of the individual traveler (the person), 
the travel destination (the place), and the use of preventive 
anti-mosquito measures and adequate chemoprophylaxis 
(prevention without and with drugs).4 In the present study, 
based on two different data sources, signals for neuropsychiatric 
event were not detected. Importantly, if a signal is not detected, 
it is impossible to determine whether no AEs (neuropsychiatric 
event in our case) exist or whether the data are insufficient.27 
Further studies are needed to substantiate this hypothesis. 
Nevertheless, as our data pertinent to the second database 
were rooted in RCTs, our estimation of signal detection is less 
likely to exhibit bias. Additionally, approximately one in seven 
individuals with neuropsychiatric contraindications received a 
prescription for MFQ prior to combat deployment.15 Travelers 
and the deployment groups cannot necessarily be equated. 
Deployment may result in psychiatric casualties that are either 
the result of inadequate coping with deployment stressors or 
acute stress reactions caused by battle trauma or combat stress 
reactions.31 Stress-inducing factors compounded to the effect 
of MFQ may be a likely cause of neuropsychiatric events in 
this population. In pharmacovigilance and in medicine in gen-
Table 4 Distribution of serious adverse events in preventing malaria in travelers
Study reference no Year of publication MFQ Comparator Adverse events
20 2003 36 34a Dermatological reaction
1 2001 15 12a Do
20 2003 89 88a gastrointestinal symptoms
1 2001 94 77a gastrointestinal symptoms
20 2003 118 109a Neuropsychiatric
1 2001 139 69a Do
1 2001 10 4a Serious adverse events
20 2003 0 0a Do
21 1997 22 22b Dermatological reaction
20 2003 45 42b Do
21 1997 29 16b gastrointestinal symptoms
20 2003 89 81b Do
22 1990 64 58b Do
20 1997 38 22b Neuropsychiatric
1 2003 118 115b Do
22 1990 10 6b Do
Notes: aComparator is atovaquone-proguanil; bcomparator is doxycycline. Derived from primary studies included in Jacquerioz and Croft.4
Abbreviation: MFQ, mefloquine.
Table 5 Reporting odds ratio and 95% CI data-mining algorithm 
for mefloquine alone
Exposure Neuropsychiatric  
events
Other  
AEs
Total
Mefloquine 31 46 77
Other antimalarial drugs 12 35 47
Total 43 81 124
ROR: A/B 
C/D 
95% CI
1.58 
 
1.49–1.68
Note: Data derived from Table 3.
Abbreviations: AE, adverse event; CI, confidence interval; ROR, reporting odds ratio.
Table 6 Reporting odds ratio and 95% CI data-mining algorithm 
for mefloquine in travelers
Neuropsychiatric Others AEa
Mefloquine 257 286
Other antimalarial 200 266
ROR: A/C 
B/D 
95% CI
1.195 
 
0.94–1.44
Notes: Data derived from Table 4; afocusing on gastrointestinal symptoms.
Abbreviation: AE, adverse event; CI, confidence interval; ROR, reporting odds ratio.
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eral, it is important to be cognizant of interactions, not only 
between drugs but also between drugs and diseases as well as 
environmental factors. As such, nondrug interactions may act 
as confounders when they are actually co-precipitating factors25 
in this special population.
We were unable to identify a signal for detection based 
on two datasets in which study time and participants were not 
the same. Thus, whether drug-events were related to MFQ-
related neuropsychiatric effects did not vary significantly 
over time. Second, there was a relatively higher frequency 
of neuropsychiatric AEs related to MFQ than to comparator 
drugs although they were not related to SAEs. This highlights 
the need for clinical surveillance of MFQ chemoprophylaxis 
with stratification by gender or age group.
Notably, no individual approach to detect signals (ROR 
in our case) is adequate and the concurrent use of other 
methods is therefore essential.32 Further incorporation of 
pharmacovigilance principles into clinical practice and aca-
demic medicine is necessary.6 As such, published studies have 
postulated that neurologic syndromes in patients induced by 
MFQ were likely due to a central anticholinergic syndrome.32 
Although multiple factors may have contributed to cognitive 
impairment, the temporal relationship between symptom 
onset and MFQ use suggests a high likelihood that MFQ was 
the causal factor;33 hence, further studies are warranted. There 
may be important differences between the pharmacokinetic 
properties of MFQ in pregnancy and nonpregnant adults.34 
Moreover, we recommend future studies assessing SAE of 
MFQ for preventing malaria in pregnant women.
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